This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Antibody responses to 5680 peptides were detected only with GM-CSF as an adjuvant.
Why it matters
Understanding how GM-CSF influences antibody production can improve vaccine strategies for prostate cancer. This research suggests that antibody responses may not reliably indicate immune spread, prompting a reevaluation of assessment methods.
How the study worked
The study evaluated sera from prostate cancer patients in four clinical trials, using a peptide array of 177,604 peptides.
What this study cannot tell us
The study focuses on antibody responses and does not assess T cell responses directly, which may provide a more accurate measure of immune spread.
Read the original research
GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.
Cancer immunology, immunotherapy : CII, 71(9), 2267-2275
Citation
Potluri, Hemanth K; Ng, Tun L; Newton, Michael A; McNeel, Douglas G. (2022). GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.. Cancer immunology, immunotherapy : CII, 71(9), 2267-2275. https://doi.org/10.1007/s00262-022-03150-3